The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study
Journal of Crohn's and Colitis · 31.05.2024 · 18 (5) · 762-772
DOI: 10.1093/ecco-jcc/jjad192 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 11.11.2023. Verfasst von Bram Verstockt und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Landos Biopharma, Inc.
Abstract (Originalsprache)
Background and Aims NX-13 activation of NLRX1 reduces intracellular reactive oxygen species and decreases inflammation in animal models of colitis. A phase 1a trial demonstrated a gut-selective pharmacokinetic profile with good tolerability. This phase Ib study aimed to evaluate the safety, tolerability, and pharmacokinetics of NX-13 in patients with active ulcerative colitis [UC].
Methods
We conducted a multicentre, randomized, double-blind, placebo-controlled trial of NX-13 in patients with active UC. Patients with a Mayo Clinic Score of 4–10 were randomly assigned [3:3:3:1 ratio] to three NX-13 oral dose groups (250 mg immediate release [IR], 500 mg IR, or 500 mg delayed release [DR], or placebo) once daily for 4 weeks. Safety and pharmacokinetics were the primary and secondary objectives, respectively.
Results
Thirty-eight patients [11 females] were recruited and randomized to placebo [five], NX-13 250 mg IR [11], NX-13 500 mg IR [11], or NX-13 500 mg DR [11] and received at least one dose. There were no serious adverse events or deaths during the trial. One patient [500 mg DR, 1/11] withdrew due to worsening of UC and a second [500 mg IR, 1/11] on the last day of treatment after a panic attack associated with atrial fibrillation. In the efficacy population [36 patients], clinical improvement in rectal bleeding and stool frequency scores relative to placebo were seen as early as week 2 and endoscopic response was seen at week 4.
Conclusions
NX-13 was generally safe and well tolerated with early signs of rapid symptom and endoscopic improvement. This novel mechanism of action warrants further investigation. ClinicalTrials.gov: NCT04862741.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
- Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
- INSERM, NGERE, University of Lorraine, F-54000 Nancy, France.
- INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
- FHU-CURE, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
ORCID-Profile: Bram Verstockt, Severine Vermeire, Rebecca Mosig, Britta Siegmund, Remo Panaccione, Silvio Danese
Förderung
- NIDDK NIH HHS
- Landos Biopharma, Inc
Zitieren
APA
Verstockt, B., Vermeire, S., Peyrin-Biroulet, L., Mosig, R., Feagan, B. G., Colombel, J. F., Siegmund, B., Rieder, F., Schreiber, S., Yarur, A., Panaccione, R., Dubinsky, M., Lichtiger, S., Cataldi, F., & Danese, S. (2024). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's and Colitis, 18(5), 762-772. https://doi.org/10.1093/ecco-jcc/jjad192
Vancouver
Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan BG, Colombel JF, et al. The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's and Colitis. 2024;18(5):762-772. doi:10.1093/ecco-jcc/jjad192
BibTeX
@article{Verstockt2024,
author = {Verstockt, Bram and Vermeire, Severine and Peyrin-Biroulet, Laurent and Mosig, Rebecca and Feagan, Brian G and Colombel, Jean-Frederic and Siegmund, Britta and Rieder, Florian and Schreiber, Stefan and Yarur, Andres and Panaccione, Remo and Dubinsky, Marla and Lichtiger, Simon and Cataldi, Fabio and Danese, Silvio},
title = {The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study},
journal = {Journal of Crohn's and Colitis},
year = {2024},
volume = {18},
number = {5},
pages = {762--772},
doi = {10.1093/ecco-jcc/jjad192}
}
EUVIMED